Recruiting studies: Hepatic Artery Infusion

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Pa
Phase 3 · 60 location(s) · ECOG-ACRIN Cancer Research Group · NCT05863195 HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06333561 DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397235 HAIC Compared With TACE in Huge Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06641713 Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unrese
Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT06406634 Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
Phase 2 · 1 location(s) · Michael J Cavnar, MD · NCT07201519 Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepati
Phase 2 · 7 location(s) · University Hospital, Montpellier · NCT03364530 Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced
Phase 2 · 1 location(s) · West China Hospital · NCT06859684 FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of P
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07012798 Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein T
Phase 2 · 1 location(s) · First Hospital of China Medical University · NCT07483359 Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Phase 2/Phase 3 · 11 location(s) · UNICANCER · NCT06904170 PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
Phase 2 · 1 location(s) · West China Hospital · NCT06742424 Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcin
Phase 2 · 1 location(s) · Northern Jiangsu People's Hospital · NCT07337421 Hepatic Artery Transfusion of NKG2D CAR-NK Cells Followed by Intravenous Infusion of NKG2D CAR-T Cells to Treat Patients
Phase 1 · 1 location(s) · Zhejiang University · NCT07021534 Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06041477 Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unr
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06852287 Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05751343 Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Poten
Phase 2/Phase 3 · 2 location(s) · Shanghai Zhongshan Hospital · NCT06796803 Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT03949231 Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
Phase 1/Phase 2 · 2 location(s) · Zhejiang Cancer Hospital · NCT06741020 PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Color
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05286814 Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Trac
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT07636798 Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06904183 Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06031285 HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectabl
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06244225 QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07327788 Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Phase N/A · 2 location(s) · Ze-yang Ding, MD · NCT05713994 HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
Phase 2 · 3 location(s) · Sun Yat-sen University · NCT06737913 HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
Phase 3 · 1 location(s) · Binkui Li · NCT07594340 Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside
Phase 2 · 1 location(s) · Erasmus Medical Center · NCT06888063

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.